176 results
Page 3 of 9
8-K
6ybr61ofkrjj 2k
17 Dec 19
ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
6:37am
8-K
EX-99.1
g7k87xjq3l0y9 p90hl
30 Sep 19
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
8:08am
8-K
EX-99.1
liss5js2
2 Nov 18
ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results
6:36am
424B5
47tdw4 8vx2s
7 Jun 18
Prospectus supplement for primary offering
4:31pm
424B5
gakeuchggm8nd c8m
5 Jun 18
Prospectus supplement for primary offering
5:17pm
8-K
EX-99.1
3cbcbobh75pfyumd3e3c
4 May 18
ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results
6:36am
10-KT
fjk4b407nfvc uc5
3 Mar 17
Annual report (with FYE transition)
12:00am